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ATSee Covering the Cover synopsis on page 670.
BACKGROUND & AIMS: Chronic intestinal pseudo-
obstruction (CIPO) is characterized by severe intestinal
dysmotility that mimics a mechanical subocclusion with
no evidence of gut obstruction. We searched for genetic
variants associated with CIPO to increase our understanding
of its pathogenesis and to identify potential biomarkers.
METHODS: We performed whole-exome sequencing of
genomic DNA from patients with familial CIPO syndrome.
Blood and lymphoblastoid cells were collected from patients
and controls (individuals without CIPO); levels of messenger
RNA (mRNA) and proteins were analyzed by quantitative
reverse-transcription polymerase chain reaction, immuno-
blot, and mobility shift assays. Complementary DNAs were
transfected into HEK293 cells. Expression of rad21 was
suppressed in zebrafish embryos using a splice-blocking
morpholino (rad21a). Gut tissues were collected and
analyzed. RESULTS: We identified a homozygous mutation
(p.622, encodes Ala>Thr) in RAD21 in patients from a
consanguineous family with CIPO. Expression of RUNX1, a
target of RAD21, was reduced in cells from patients with
CIPO compared with controls. In zebrafish, suppression of
rad21a reduced expression of runx1; this phenotype was
corrected by injection of human RAD21 mRNA, but not with
the mRNA from the mutated p.622 allele. rad21a Morpholino
zebrafish had delayed intestinal transit and greatly reduced
numbers of enteric neurons, similar to patients with CIPO.
This defect was greater in zebrafish with suppressed
expression of ret and rad21, indicating their interaction in the
regulation of gut neurogenesis. The promoter region of APOB
bound RAD21 but not RAD21 p.622 Ala>Thr; expression of
wild-type RAD21 in HEK293 cells repressed expression of
APOB, compared with control vector. The gut-specific isoform
of APOB (APOB48) is overexpressed in sera from patients
with CIPO who carry the RAD21 mutation. APOB48 also is
overexpressed in sporadic CIPO in sera and gut biopsy
specimens. CONCLUSIONS: Some patients with CIPO carry
mutations in RAD21 that disrupt the ability of its product toregulate genes such as RUNX1 and APOB. Reduced expression
of rad21 in zebrafish, and dysregulation of these target genes,
disrupts intestinal transit and the development of enteric
neurons.Keywords: Sporadic and Familial Chronic Intestinal Pseudo-
obstruction; Intestinal Motility; Animal Model; Genetic Analysis.
hronic intestinal pseudo-obstruction (CIPO), a rareCand potentially life-threatening disorder with
unknown prevalence and incidence,1–3 is viewed typically
as an insufficiency of the intestinal peristalsis that mimics
a subocclusive disease in the absence of mechanical
obstructions.4–6 The severity of the clinical presentation and
the limited understanding of the disorder contribute to poor
quality of life and increased mortality.2,4–7 In addition, there
are no specific biochemical or molecular biomarkers of CIPO,
further hindering a correct diagnosis. From a genetic
perspective, most patients with CIPO experience sporadic
occurrences, although X-linked, autosomal-dominant, and
recessive forms have been identified with mutations in filamin
A,8,9 actin G2,10 thymidine phosphorylase11/polymerase g,12
and, more recently, in SGOL1.13 However, the underlying ge-
netic alterations and molecular mechanisms remain unknown
in most CIPO cases.
We previously mapped a locus in a large consanguineous
family, segregating an autosomal-recessive form of CIPO.14,15
In the affected family members, the major clinical feature
was represented by CIPO, in addition to megaduodenum,




ATlong-segment Barrett esophagus, and cardiac abnormalities
of variable severity (OMIM 611376; Mungan syndrome).
Here, we intersected mapping data with whole-exome
sequencing to identify RAD21 as a causal locus for CIPO.
Our combined genetic and functional data suggest a loss-of-
function mechanism that disrupts the structure and func-
tion of enteric innervation. Moreover, based on our previous
observations that identified apolipoprotein B (APOB) as a
target of RET signaling,16 we explored the role of this protein
in CIPO etiopathology in the context of RAD21 mutations.
Here, we report a key role for APOB48, a gut-specific iso-
form,17 as a transcriptional target of RAD21, and thus a
contributor to CIPO, with potential utility as a biomarker.
Materials and Methods
Patients and Controls
The clinical characteristics of the patients with syndromic
CIPO are indicated in the Supplementary Material and Methods
section. An additional 21 Italian and 12 Swedish sporadic pa-
tients with idiopathic CIPO were included in the study (8 men
and 25 women; mean age, 38.6 ± 16.6 y). Table 1 shows the
major clinical characteristics of these patients. Five hundred
Turkish controls were recruited at the Universities of Ankara
and Istanbul; 240 controls of European ancestry were recruited
at the University of Bologna. All data from patients and con-
trols, including informed consent, were handled in accordance
with local ethical committee–approved protocols and in
compliance with the Helsinki declaration (http://snp.gs.
washington.edu/SeattleSeqAnnotation137).
High-Throughput Single-Nucleotide
Polymorphism Genotyping and Whole-Exome
Sequencing Analysis
A detailed description of the single-nucleotide poly-
morphism (SNP) genotyping and whole-exome sequencing
analysis is reported in the Supplementary materials. Variant
detection and genotyping were annotated with the Seat-
tleSeq137 Annotation Server.
RAD21 Mutation Screening in Idiopathic
CIPO Cases
Genomic DNA extracted from peripheral blood was ampli-
fied as reported in the Supplementary materials.
RAD21 Complementary DNA Transfection
Into HEK293 Cells
HEK293 cells (3  105) were plated for transfection of the
different plasmids using liposomes as described in the
Supplementary materials.
Gene Expression Analysis
Total RNA from 1.5 mL fresh blood was extracted with the
Qiagen Blood Total RNA kit (Qiagen, Venlo, Limburg, The
Netherlands). Total RNA from lymphoblastoid or transfected cells
was extracted with the RNeasy kit (Qiagen). Real-time quantita-
tive reverse-transcription polymerase chain reaction (RT-PCR)
was performed as reported in the Supplementary materials.Zebrafish Functional Assays
To determine the effect of rad21a suppression in zebrafish
embryos, a splice-blocking morpholino (MO) was designed as
described in the Supplementary materials. A published ret MO
was used.18 To measure rad21a MO efficiency, total messenger
RNA (mRNA) was extracted from control and MO-injected
embryos, reverse-transcribed, and the site targeted by the MO
was PCR-amplified (Supplementary Figure 1). runx1 expression
analysis and enteric nervous system characterization are
reported in the Supplementary materials.
Microgavage
Control and rad21 MO-injected embryos were developed
until 5 days postfertilization (dpf). Zebrafish larvae were
anesthetized in Tricaine (Sigma, St. Louis, MO), mounted in 3%
methylcellulose, and injected with fluorescent beads into the
mouth as described.19
Electromobility Shift Assay
LCLs (2  106) were processed for nuclear extract prepa-
ration as described in the Supplementary materials.
Immunoprecipitation and Western Blotting
Lymphoblastoid cell lines (LCLs) (2  106) were used for
immunoprecipitation assays. Crude sera of patients was diluted
in phosphate-buffered saline. Serial dilutions for cases and
controls were performed (1:5, 1:10, and 1:100) (Supplementary
Figure 2A). Immunoprecipitation and Western blotting were
performed as reported in the Supplementary materials.
Immunohistochemistry
Immunohistochemistry was performed as reported in the
Supplementary materials. Incubation with the corresponding
blocking peptides or with the secondary antibodies only
were performed as negative controls (Supplementary Figure 2B
and C).
Quantitative Evaluation of Ganglion Cells
Quantitative evaluation of neuron number in myenteric and
submucosal ganglia was performed according to Ganns et al20
(Supplementary materials).
Statistical Analysis
A case-control association study for SNP rs72105712 was
performed using Haploview 4.0 (http://www.broadinstitute.
org/scientific-community/science/programs/medical-and-pop
ulation-genetics/haploview/). A statistical analysis of quantita-
tive differences was performed using the Student t test from the
GraphPad package (http://graphpad.com/quickcalcs/). A fluo-
rescent cell countwasperformedwith ImageJ (National Institutes
of Health, Bethesda, MD) (http://rsbweb.nih.gov/ij); chi-squared
tests were calculated using the dedicated option from GraphPad.
Results
Identification of a Novel RAD21 Mutation in CIPO
We performed a combined SNP-genotyping/next
generation-sequencing approach in a consanguineous
April 2015 Molecular Genetics of Severe Gut Dysmotility 773CIPO pedigree of Turkish origin (Figure 1A), in which we
previously mapped a linkage locus with a multipoint loga-
rithm (base 10) of odds score of 5.019.14 High-throughput
SNP genotyping in the family and detection of runs of ho-
mozygosity by PLINK (http://ngu.mgh.harvard.edu/
wpurcell/plink/) confirmed the locus14 by identifying 2Table 1.Clinical Characteristics of Idiopathic CIPO Patients Inc
Patient
reference code Age, y Sex Feeding
SWE_CIPO004 60 F Oral Sev
SWE_CIPO010 44 F Oral þ PPN BUP
SWE_CIPO035 60 F Oral þ PPN Abn
SWE_CIPO042 56 F TPN —
SWE_CIPO094 61 F Oral Abn
p
SWE_CIPO095 49 F Oral BUP
SWE_CIPO096 56 F Oral BUP
c
SWE_CIPO097 41 F EN þ PPN BUP
SWE_CIPO099 50 F Oral þ PPN BUP
SWE_CIPO149 37 M TPN Bow
SWE_CIPO245 41 F Oral þ PPN Bow
SWE_CIPO247 20 F TPN Bow
ITA_CIPO08 17 M EN Bow
ITA_CIPO27 39 F Modified oral Abn
p
ITA_CIPO15 38 F Modified oral Abn
ITA_CIPO18 40 F Modified oral —
ITA_CIPO22 26 M EN/oral Abn
p
ITA_CIPO10 56 M EN —




ITA_CIPO23 22 M EN/oral Abn
p
ITA_CIPO38 44 F Oral Abn
p
ITA_CIPO13 25 F Oral BUP
f
ITA_CIPO36 18 F Oral —
ITA_CIPO29 1 M Oral —
ITA_CIPO39 16 F EN/oral —
ITA_CIPO26 18 F Oral Abn
p
ITA_CIPO25 40 M EN/oral Abn
p
ITA_CIPO24 35 F EN/oral Abn
p
ITA_CIPO16 67 F EN/oral —
ITA_CIPO14 40 F EN Irreg
c
ITA_CIPO33 20 M EN/oral Abn
p
ITA_CIPO17 54 F EN Lac
c
c
ITA_CIPO30 46 F Modified oral —
AF, activity front; BUPA, bursts of uncoordinated phasic activ
partial parenteral nutrition; SPUPA, sustained periods of uncooregions of extended homozygosity: 91,878,147–113,307,176
and 116,713,296–124,956,205 (Supplementary Table 1). We
then performed whole-exome sequencing on genomic DNA
from 2 affected individuals (IV-9 and IV-11) (Figure 1A). We
filtered data for variants that were (1) homozygous in our
patients; (2) rare (minor allele frequency [MAF] <1%) inluded in the RAD21 Mutation Screening
Intestinal manometry Histopathology
ere hypomotility Inflammatory neuropathy;
severe depletion of ICC
A and absence of feeding activity Inflammatory neuropathy







onfigured and propagated AFs
Degenerative neuropathy;
vacuolar myopathy
A; absence of feeding activity Inflammatory neuropathy
A; SPUPA Degenerative neuropathy
el dilatation Inflammatory neuropathy
el dilatation Degenerative myopathy;
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el dilatation Degenerative myopathy
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Figure 1. Identification of a
novel homozygous muta-
tion in RAD21. (A) Pedigree
of the Turkish consanguin-
eous family showing the
segregation of the RAD21
mutation in the available
members. For the homozy-
gous patients, electrophe-
rograms are boxed in red.






lighted in red). (C) RUNX1
expression in controls and
patient LCLs (IV-9).




ATpublic databases (Exome Variant Server, Database of Short
Genetic Variations); and (3) predicted computationally to be
pathogenic. We found a single variant that fulfilled all these
conditions inside our linkage interval on chromosome 8
(Figure 1 and Supplementary Figure 3A). This homozygous
allele affects the coding change c. 1864 G>A in RAD21
(NM_006265.2), and is predicted to generate a missense
substitution p.622 Ala>Thr (Figure 1B). Mutation Taster
(http://www.mutationtaster.org/) and PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/)21 analysis predicted this
change to be “disease causing” and “damaging,” respectively
(Mutation Taster P ¼ .9999; PolyPhen-2 HumDiv score,
0.999; sensitivity, 0.14; specificity, 0.99; HumVar score, 0.993;sensitivity, 0.47; specificity, 0.96), and the variant was absent
from public databases (dbSN: www.ncbi.nlm.nih.gov/SNP/;
1000 Genomes: www.1000genomes.org/; NHLBI Exome
Sequencing Project (ESP): http://evs.gs.washington.edu/EVS/),
and from 1000 control chromosomes of Turkish origin
analyzed by our group. To test the candidacy of this allele,
we performed a segregation analysis on all available family
members: all 3 affected siblings carried the change in a
homozygous state and all carriers of the risk haplotype
(including the parents) were heterozygous (Figure 1A).
To evaluate whether RAD21 mutations also were
prevalent in other idiopathic CIPO cases, we screened 21
Italian and 12 Swedish individuals with pseudo-obstruction,













ATdefined by clinical, manometric, and radiologic examination
(Table 1). We did not identify any mutation in the RAD21
coding region, although a 1-bp indel was detected with high
frequency in the upstream region (MAF, 0.364; g.11788122-
11788123 ins[C]; rs72105712 [dbSNP137]). Because no
allele frequencies were known for this SNP, we investigated
the frequency in a control group of European ancestry (N ¼
240); we found no differences between cases and controls
(MAF, 0.36 in cases and 0.34 in controls; c2 ¼ 0.08; P ¼ .77).
Mutant RAD21 p.622 Ala>Thr Alters
RUNX1 Expression
To test the candidacy of RAD21 further, we evaluated its
expression in blood and LCLs obtained from 1 homozygous
patient and several controls, including 1 unaffected wild-
type brother. Real-time quantitative RT-PCR showed that
RAD21 expression in the affected individual was comparable
with that in controls, either in blood (Supplementary
Figure 3B) or in LCL complementary DNA (cDNA)
(Supplementary Figure 3C). The mutant protein also was
expressed in LCLs in amounts comparable with wild-type
cells (Supplementary Figure 3D, upper panel). Likewise,
testing the interaction of RAD21 with SMC1, one of its
known partners,22 in co-immunoprecipitation experiments
showed that the mutant protein still retains SMC1-binding
activity (Supplementary Figure 3D, middle panel).
Because one of the main target genes activated by
RAD21 is RUNX123,24 we investigated whether mutated
RAD21 could hamper its transcription activity. Indeed, the
affected individual’s LCLs showed significantly reduced
RUNX1 expression compared with controls (Figure 1C).
Similarly, transfection of mutant RAD21 cDNA in HEK293
cells and subsequent quantitative RT-PCR showed a signif-
icant decrease in RUNX1 expression (P ¼ .0028, Student
t test) compared with cells transfected with wild-type
RAD21 cDNA (Supplementary Figure 3E).
Rad21a Suppression Causes Down-regulation
of runx1 Expression and Loss of Enteric
Neurons In Vivo
To test the hypothesis that RAD21 is necessary for enteric
development and to assay the pathogenic potential of the
newly discovered allele in a physiologically relevant in vivo
system, we investigated RAD21 in zebrafish development.
Given our in vitro observations on the role of RAD21 on
RUNX1 expression and its down-regulation in patient cells,
we asked whether RAD21 can replicate this defect in vivo
and whether the patient’s mutation has the expected effect.
We identified (by reciprocal BLAST) the sole ortholog of
RAD21 and we injected zebrafish embryos with a rad21a
splice-blocking MO (at 1–2 cell stage; Supplementary
Figure 2A and B). Embryos were fixed at 14 hours post-
fertilization and stained with a runx1 probe. During zebra-
fish development, runx1 is expressed in the posterior lateral
plate mesoderm. We observed defects in runx1 expression
patterns recapitulating prior studies,23,24 with runx1
expression either partially or completely absent in rad21a
morphants (Figure 2A–C). Runx1 expression was rescued byco-injection of MO with human WT RAD21 mRNA. In
contrast, co-injection of MO and mRNA encoding the p.622
Thr allele was not able to rescue runx1 expression, indi-
cating that the RAD21 mutation has a loss-of-function effect
in vivo (Figure 2D).
To test whether we could recapitulate the CIPO phenotype
seen in RAD21 mutant patients, including a severe impair-
ment of gut motility and marked hypoganglionosis,14 we
characterized the zebrafish gut. Subsequent to MO injection,
embryos were allowed to develop to 5 dpf, at which time the
digestive system had developed.25 Notably, we saw no
appreciable runx1 expression in the gut at this stage of
development (data not shown), suggesting an earlier onset of
the enteric phenotype. Control and MO embryos were fed
fluorescent beads through microgavage, a technique that
allows determination of the rate of intestinal motility as a
function of time.19 After 8 hours postbead injection, embryos
were divided into 1–4 zones based on anatomic landmarks
(Figure 3A), and the presence of fluorescence in each segment
was scored. Consistent with the CIPO phenotype, rad21a
morphants showed delayed food transit along the gut
(Figure 3B). Moreover, staining of enteric neurons along the
gut with antibodies against HuC/D showed significant
depletion of enteric neurons (Figure 3C). Quantitative analysis
of the zebrafish gut (Figure 3D) at 4 (Figure 3D, upper panel)
and 5 (Figure 3D, lower panel) dpf stages showed that rad21
morphants had a marked reduction of HuC/D-immunolabeled
enteric neurons compared with controls, suggesting a
neurogenic cause of the observed motility defects.
Notably, previous reports on rad21a morphants and
rad21nz171 mutants have shown significantly reduced
expression of ascl1a,26 a neuronal marker. Ascl1 is also a
transcription factor that is required for the development of
serotonergic neurons.26 An ASCL1 mutation was reported
previously in Haddad syndrome, a condition that encom-
passes congenital central hypoventilation syndrome and
Hirschsprung disease (MIM 209880).
These data, the similarity of rad21a morphants to the
hypoganglionic phenotype observed in a mouse model for
the ret mutation C620R,27,28 raised the possibility that
RAD21 and RET might act synergistically during gut neuro-
genesis. We therefore performed epistasis analysis by co-
injecting rad21a and ret MOs at subeffective doses, at
which each MO alone was indistinguishable from control
embryos. We observed strong epistasis on the innervation of
the gut; co-injection of the 2 genes phenocopied the pheno-
type of high-dose rad21 MOs (Figure 3E and F). At the same
time, overexpression of RET did not rescue rad21morphants,
or vice versa, suggesting that the 2 genes act on the same
process but not directly in the same pathway. This obser-
vation was consistent with previous studies that showed RET
to be induced by NGF in a runx1-independent manner.29The Mutant RAD21 p.622 Ala>Thr Does Not
Bind to RAD21-Binding Elements in
Apolipoprotein B Promoter
Recent data have shown that RAD21/CTCF binding
sites are present in the apolipoprotein A1/C3/A4/A5 gene
Figure 2. RAD21 A622T affects runx1 expression in zebrafish embryos. runx1 expression in the posterior lateral plate
mesoderm in rad21a MO-injected embryos rescued with wild-type or mutant RAD21. Morpholino-injected embryos were
scored according to runx1 expression in the posterior lateral plate mesoderm as follows: (A) normal, (B) partial, or (C) absent.
rad21a morphants could be rescued by wild-type human RAD21 mRNA, whereas mutations previously reported in patients
with cohesinopathy (P376A, C585R) and A622T cannot rescue this phenotype.




ATcluster on chromosome 11 and that altered binding of
these factors to these sites dysregulates apolipoprotein
expression.30 We therefore performed electromobility
shift assay experiments to test whether the mutant RAD21
protein could retain its binding affinity for the earlier-
mentioned sites, in particular for the AC2 site.30 We
observed no differences between the nuclear extracts
from wild-type and mutant LCLs in binding to this site
(Supplementary Figure 3F). Next, we investigated if the
nuclear extracts from wild-type and mutant LCLs could
show differences in binding to the human APOB pro-
moter.31 In silico analysis with MatInspector (Genomatix,
Munich, Germany) identified 2 binding sites for RAD21/
CTCF (hAPOB_c1, chr2: 21,267,137–21,267,173; matrix
score, 0.862; hAPOB_c2, chr2: 21,266,910–21,266,945;
matrix score, 0.807), which maps to the 2 regulatory re-
gions of the proximal APOB promoter.31 Electromobility
shift assays performed with probes corresponding to the 2
sites showed a specific shift only in the presence of wild-
type nuclear extracts (Figure 4A). Moreover, specific
supershifts with an anti-RAD21 antibody were detectable
only in wild-type, but not in mutant, nuclear extracts
(Supplementary Figure 4A). Transfection of the plasmids
carrying either wild-type or mutant RAD21 cDNAs in
frame with the DDK-epitope, in HEK293 cells, and subse-
quent quantitative RT-PCR analysis of APOB expression,
showed that wild-type RAD21 overexpression reduced
APOB levels compared with the empty vector (P ¼ .0098;
Student t test). In contrast, overexpression of the mutant
protein had no effect, similarly to the empty-vector
transfections (Figure 4B and C). These data suggest that
RAD21 might act as a repressor of APOB.APOB Is Overexpressed in CIPO Patients
APOB transcript generates 2 different proteins, APOB48
and APOB100 isoforms, both present in serum.17 Because
our data suggested a RAD21-regulated expression of APOB,
we analyzed sera from the CIPO patient homozygous for
RAD21 mutation (IV-9), and from wild-type controls. We
detected an increased expression of APOB48 in the patient,
whereas no significant differences could be appreciated for
APOB100 (Figure 5A and Supplementary Figure 5A). To
understand whether APOB overexpression was unique to
this patient or whether it might represent a more general-
ized phenomenon, we evaluated sera from RAD21 mutation-
negative idiopathic CIPO patients and from control subjects.
CIPO patients showed an increase in APOB48 (Figure 5B
and Supplementary Figure 5B). Moreover, compared with
CIPO, sera derived from 12 patients with functional bowel
disease, namely 7 patients with diarrhea-predominant irri-
table bowel syndrome (IBS), 4 patients with constipation-
predominant IBS, and 1 patient with alternating bowel
IBS, did not show APOB48 overexpression (Figure 5C and
Supplementary Figure 5C). Furthermore, Western blot
analysis on the sera of patients with other gastrointestinal
disorders (ie, anorexia nervosa and mechanical intestinal
obstruction), did not identify any APOB48 increase (Bianco
et al, data not shown).
Immunohistochemical analysis of gut biopsy specimens
(mainly ileum) of sporadic CIPO patients showed APOB48
expression in myenteric neurons and in cells of the lamina
propria, reminiscent of immunocytes (Figure 5). Consistent
with the results obtained in the sera, the APOB48 signal was
increased markedly in the biopsy specimens of CIPO cases
compared with controls and IBS cases (Figures 5D, i-iv-vii).
Figure 3.Gut dysmotility is caused by enteric neuronal loss in zebrafish embryos. To assess gut motility in zebrafish larvae, we
injected fluorescent beads into the mouth and recorded the rate of gut motility vs time. (A) Lateral view of 5 dpf zebrafish
larvae. Representative images of injected larvae show (after 8 hours postinjection) fluorescent beads in different gut com-
partments (zones 1–4). (B) In control embryos, most of the fluorescent beads have exited the gut by 8 hours postinjection,
whereas rad21 MO-injected embryos have reduced gut motility. (C and D) Compared with control larvae, rad21 morphants
have a significant reduction of enteric HuC/D immunoreactive neurons at (D) 4 dpf (upper panel) and 5 dpf (lower panel). (E)
rad21 and ret interaction during enteric nervous system (ENS) development. A combination of suboptimal doses of rad21 and
retMOs causes a significant decrease in HuC/D enteric neurons, whereas (F) embryos injected with suboptimal doses of rad21
MO or ret MO causes a loss of HuC/D enteric neurons, which was not statistically significant.













ATThe quantitative analysis of immunolabeled cells in the
lamina propria of 8 CIPO patients (5 Italian and 3 Swedish
patients) indicated a significant increase in the number of
APOB48-positive cells compared with the other individuals
(controls, n ¼ 3; IBS patients, n ¼ 3) (32.9% ± 9.2% vs 7.2%
± 2.5% cases vs controls; P ¼ .0012, Student t test; 32.9% ±
9.2% vs 5.6% ± 1.5% CIPO cases vs IBS cases; P ¼ .0008;
CIPO cases [n ¼ 8] vs all [n ¼ 6]; P ¼ .0001)
(Figure 5Dv–vii). In addition, quantitative analysis per-
formed in the gut biopsy specimens of sporadic CIPO pa-
tients with a marked increased in APOB48 showed a
significant reduction in the number of neuron-specific
enolase–labeled myenteric ganglion cell bodies/ganglion
compared with control specimens (CIPO cases 22.71 ± 8.10
vs controls 48.65 ± 13.80; P ¼ .0039, Student t test)
(Figure 5E). No significant differences were observed for
neurons in the submucosal plexus between CIPO cases and
controls (CIPO cases 5.61 ± 0.39 vs controls 8.36 ± 2.96;
P ¼ .1079, Student t test).
We observed RAD21 staining in multiple tissues and
throughout different components of the gut, as shownpreviously (www.proteinatlas.org), although no differ-
ences were appreciated between CIPO and controls
(Supplementary Figure 6Ai–iv). The expression of APO-
BEC1, the gut-specific RNA editing enzyme responsible for
the formation of the APOB48 isoform, also was investi-
gated; we observed similar immunostaining in control and
CIPO tissue biopsy specimens (Supplementary Figure 6Bi
and Bii).Discussion
This study provides in vitro and in vivo evidence that a
novel homozygous mutation in RAD21 is associated with a
syndromic form of CIPO. RAD21 is part of the cohesin
complex, forms a physical link between SMC1/SMC3 and
STAG subunits, and controls sister chromatid pairing and
unpairing during cell replication.32 RAD21 is also a tran-
scriptional regulator that binds to many sites in the
genome.33 In concordance with the key role(s) of RAD21 in
regulating cell division, altered expression and somatic loss-
of-function mutations have been reported in different
Figure 4. RAD21 regulates APOB overexpression. (A) Elec-
tromobility shift assay on human APOB promoter containing
2 putative binding sites for RAD21: hAPOB_c1 (green) and
hAPOB_c2 (red). Electromobility shift assay analysis for
hAPOB_c1 and _c2 regions biotin-labeled probes: only the
nuclear extracts from wild-type (control) LCLs show a specific
gel-shift (black arrows). (B) Quantitative RT-PCR for APOB
expression in HEK293 cells transfected either with empty,
RAD21 wild-type, or RAD21 mutant p.622 Thr vectors. Data
represent the mean values of 3 independent transfection
experiments. Bars represent the standard deviation; black
asterisk indicates the significant P value (see text for more
detail). (C) Western blot analysis shows the expression of
recombinant wild-type and mutant RAD21 in frame with DDK
tag in transfected HEK293.




ATcancers.34,35 Furthermore, heterozygous germline mutations
in cohesin subunits (ie, RAD21, SMC1, and STAG), or in
regulators of cohesin (eg, NIPBL), cause a broad spectrum of
disorders referred to as cohesinopathies (namely, Cornelia
de Lange syndrome, OMIM 122470), characterized by facial
dysmorphisms, growth retardation, developmental delay
and/or intellectual disability, and multiorgan involvement,
including musculoskeletal malformations ranging from
brachyclinodactyly to severe reduction defects.36–39We observed a similar loss-of-function phenotype for 2
missense CdL mutations (p.376Pro>Arg, p.585Cys>Arg)
and for our CIPO variant in RAD21 (p.622Ala>Thr). How-
ever, in the consanguineous family studied herein the het-
erozygous carriers of the RAD21 mutation did not show sign
of CdLS.14 Previously described patients with Cornelia de
Lange syndrome and different RAD21 heterozygous muta-
tions did not show gastrointestinal abnormalities such as
CIPO.32,40 It is worth noting that the mutations observed in
Cornelia de Lange syndrome and in our CIPO patients map
to different RAD21 domains, potentially suggesting that
specific mutational mechanisms in RAD21 can lead to
different clinical entities in human beings. Consistent with
this notion, the CIPO-causing mutations do not appear to
abolish the ability of RAD21 to bind to SMC1, whereas it
does attenuate its transcriptional repressive role of other
targets, such as APOB.
Recently, however, a mutation in SGOL1, another cohesin
protein, was associated with severe gut and cardiac
dysrhythmia in the absence of other congenital abnormal-
ities or cohesinopathies.13
RAD21 plays an important role in the development,
survival, and maintenance of epithelial cells and neurons of
the gastrointestinal tract, and mice heterozygous for a
Rad21 null mutation show gastrointestinal defects after
X-ray irradiation.41 Our zebrafish studies suggest that rad21
is essential for enteric neuron development: rad21a mor-
phants recapitulate the CIPO phenotype because they show
delayed transit along the gut and a significant depletion of
enteric neurons. This latter finding is reminiscent of an
enteric neuronal hypoganglionic phenotype observed in
heterozygous retC620R/þ mice16 and shares similarities with
the histopathology of some CIPO patients.14,27,28 The simi-
larity of the rad21 suppression phenotype in zebrafish to
the neuronal defects of heterozygous retC620R/þ mice
prompted us to test whether those 2 genes might interact
genetically. We showed that RET and RAD21 interact epis-
tatically during differentiation or maintenance of enteric
neurons. However, the failure of the 2 genes to rescue the
gut innervation phenotype suggests that they activate
different molecular pathways.
Our previous studies identified apolipoprotein B (Apob)
as a target of RET signaling in Neuro2a cells, a murine
model of enteric nervous system development. Moreover, in
retþ/C620R mice that have an enteric neuronal hypo-
ganglionic phenotype16 reminiscent of the histopathology
observed in some CIPO patients,27,29 Apob was overex-
pressed markedly. APOB is a major constituent of the
plasma lipoprotein, and in mammals is synthesized in 2
different tissues (ie, liver and intestine). Two different
proteins derive from the APOB transcript by a RNA editing
enzyme: APOBEC1, the full-length APOB100, a large protein
of 512 kilodaltons synthesized by the liver (which does not
express APOBEC1), essential for triglyceride-rich very-low-
density lipoprotein formation; and the gut-specific isoform
APOB48, formed via the RNA editing process and co-linear
with the N-terminal half of APOB100. APOB48 has a key
role in chylomicron assembly and transport in the
intestine.17
Figure 5. APOB overexpression is specific for CIPO patients. (A) Western blot analysis shows APOB48 expression in the
patient carrying the homozygous RAD21 mutation (third lane), compared with control sera (upper panel); glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal loading control (lower panel). (B) Western blot analysis
showing APOB overexpression in the sera of CIPO patients compared with controls (upper panel). (C) Western blot analysis for
APOB48 in IBS samples vs controls (shown in black) and CIPO patients (shown in red). Samples loaded in duplicate/triplicate
are marked in bold (as an index of reproducible blotting). IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant
IBS. (D) Immunohistochemistry and immunofluorescence staining for APOB in controls (Di, iii, v), IBS cases (Dvii), and CIPO
patients (Dii, iv, vi). Representative figures (Di, ii) illustrate immunostaining of immunocyte-like cells distributed throughout the
mucosa, including the lamina propria and the myenteric plexus (Diii, iv). Note that the density of APOB immunoreactive
immunocyte-like cells in the lamina propria was higher in CIPO patients (Dvi) vs controls or IBS cases. (E) Histogram showing
the significant decrease in the number of neurons per ganglion in the myenteric plexus observed in CIPO, compared with
control tissue biopsy specimens. *P < .05













ATAPOB expression is regulated by a strong promoter in
the proximal upstream region, containing several positive
regulatory elements, including one within the noncoding
exon 1, but also a negative regulatory element between
bases -261 and -129.31 In this study we identified 2 RAD21
binding sites in the APOB proximal promoter (ie, over-
lapping the negative element, and the other partially over-
lapping the exon 1–positive regulatory element). Only
nuclear extracts from wild-type cells form a specific com-
plex with either region, whereas no complex is observed in
the presence of mutant RAD21. This suggests that RAD21may act as a repressor of APOB transcription, associating
with its negative regulatory element and competing with the
transcriptional activators that bind to the positive regula-
tory element.
Finally, we found that, compared with controls, gut-
specific APOB4817 levels were increased in the serum of
the RAD21-mutated CIPO patient. Interestingly, sera from
the sporadic CIPO patients, negative for RAD21 mutations,
also showed consistently increased APOB48 levels com-
pared with either IBS patients or healthy controls. We
observed a variable expression of APOB100 in both controls
Figure 6.Model of RAD21 functioning as (A) cohesin complex
or as (B) transcription factor. (A) RAD21 belongs to the
cohesin complex regulating chromosomal replication. RAD21
p.622Thr does not alter SMC1A subunit binding. (B) Wild-
type RAD21 promotes RUNX1 and represses APOB expres-
sion. RAD21 p.622Thr down-regulates RUNX1 expression,
de-represses APOB expression, and leads to ENS neuron
loss with resultant hypoganglionosis. Alternative pathways,
including RET abnormal activation (eg, the p.620 Cys>Arg
mutation [red asterisk] in heterozygous mice) can lead to
APOB overexpression, which is associated phenotypically
with hypoganglionosis.




ATand CIPO patients, in line with the fact that its regulation
depends on different factors, including cholesterol and in-
sulin levels.42 Notably, CIPO patients did not show evidence
of altered lipid metabolism (ie, total cholesterol and high-
density lipoprotein levels were within the normal range)
(Supplementary Table 2).
APOB48 overexpression was corroborated further by the
data on gut biopsy specimens from CIPO patients. Comparedwith controls, APOB48 immunoreactivity was increased
significantly in cells (with morphologic features of immu-
nocytes) distributed throughout the lamina propria and in
myenteric neurons of CIPO patients.
Interestingly, a recent study identified a specific neuron-
macrophage cross-talk in regulating gut motility.43 These
data bear implications to the pathogenesis of functional
bowel disorders, such as IBS. However, our study did not
show any change in APOB expression in patients with IBS,
suggesting that other molecular pathways also can be
involved in patients with a more prominent gut dysfunction
such as those with CIPO.
Furthermore, we found a significant decrease in the
mean number of myenteric neurons/ganglion in CIPO tis-
sues showing a high APOB immunoreactivity. This finding is
reminiscent of severe hypoganglionosis14 in the patients
who were found to carry the RAD21 p.622Ala>Thr homo-
zygous mutation in this study.
Based on our data, APOB48 expression (at serum and
tissue levels) was increased homogeneously in sporadic and
familial CIPO and therefore there is a possible correlation
between this marker and the degree of neuronal loss or
undetectable symptom severity. Further studies eagerly are
awaited to clarify whether a correlation between APOB
expression levels and neuronal/clinical CIPO phenotype
exists.
The pathophysiological significance of the generalized
APOB overexpression observed in sporadic CIPO, in which
no mutation of RAD21 was identified, currently is unclear.
Our previous studies suggested a role for APOB in the
molecular pathways required for enteric neuron devel-
opment and survival.16 Therefore, APOB48 increase may
be activated as a compensatory effect of an abnormal/
defective enteric nervous system occurring in CIPO. We
still do not know the precise temporal origin of the defect
that leads to CIPO in patients with RAD21 mutations. The
observed transcriptional down-regulation of runx1, which
likely is relevant in early neuronal progenitors, possibly in
the crest, argues for a migratory defect. At the same time,
the observed loss of APOB suppression might be more
relevant to neuronal progenitors in the gut itself
(Figure 6). Further studies of patients and conditional
mouse mutants will be required to understand the
potential relative contribution of different sites to CIPO
pathology. Likewise, further research will be required to
elucidate the factors contributing to the specific APOB48
overexpression and its clinical value in the management of
CIPO patients. Nonetheless, our data inform the molecular
aspects underlying the pathogenesis of CIPO and lead to
the identification of a candidate biomarker, namely
APOB48 overexpression, for this severe disabling gut
dysmotility disorder.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2014.12.034.
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Supplementary Materials and Methods
Familial Turkish CIPO patients
The 2 brothers and sister, aged 26, 28, and 30 (IV-9, IV-
10, and IV-11) (Figure 1A) presented with recurrent
abdominal pain and pseudo-obstruction since childhood.
The proband IV-10 presented with episodes suggestive
of intestinal obstruction since childhood (age, 11 y) and
underwent repeated abdominal surgeries, although exten-
sive investigation failed to detect any structural obstacle to
transit. Endoscopic evaluation of the esophagus showed a
long-segment Barrett esophagus extending up to 18 cm, and
no evident abnormalities in the stomach. Esophageal
manometry showed aperistalsis and undetectable lower
esophageal pressures, and barium small-bowel enema
showed megaduodenum and delayed emptying. The patient
died at 29 years of age from complications of a surgical
procedure prompted by intestinal perforation, while he was
on total parenteral nutrition.
His brother (IV-9) had a similar long-lasting history of
multiple hospitalizations and surgical procedures owing to
recurrent subocclusive episodes. He presented virtually
identical findings at upper-gastrointestinal endoscopy and
esophageal manometry. However, his clinical features also
included otosclerosis, glaucoma, and epilepsy. Cardiac abnor-
malities included pulmonary and tricuspid valve insufficiency.
Their sister, IV-11, is a 30-year-old woman with an apparently
milder form of CIPO characterized only by sporadic radio-
logically confirmed subocclusive episodes (ie, air-fluid levels
in distended bowel loops). Digestive symptoms were associ-
ated with malnutrition and amenorrhea. Endoscopy showed
long-segment (up to 14 cm) Barrett esophagus, intragastric
bezoars, and megaduodenum. Functional tests provided re-
sults similar to those observed in her affected brothers,
namely delayed gastric emptying and severe dysmotility (ie,
aperistalsis with simultaneous contractions, undetectable
lower esophageal sphincter pressure) at esophageal manom-
etry. A male and female cousin, also born of consanguineous
parents, were reported to have gastrointestinal complaints
and died at 19 and 15 years of age, respectively. The female
cousin who died at age 15 had clinical and radiologic evidence
of CIPO, as well as renal hypoplasia, vesico-ureteral reflux,
ascites, and unspecified granulomatous hepatitis.
High-Throughput SNP Genotyping
A total of 400 ng of genomic DNA from peripheral blood
was used for high-throughput SNP genotyping on an Illu-
mina Infinium HD Assay Gemini platform (Illumina, San
Diego, CA), according to the manufacturer’s protocol.
Genotypes were converted into PLINK format with
custom scripts. PLINK v1.07 (http://ngu.mgh.harvard.edu/
wpurcell/plink/) was used to isolate individual runs of
homozygosity that showed more than 1 Mb overlap be-
tween the 3 affected siblings.
Whole-Exome Sequencing Analysis
A total of 1 mg of genomic DNA was subjected to a
series of shotgun library construction steps, including
fragmentation through acoustic sonication (Covaris,
Woburn, MA), end-polishing and A-tailing, ligation of
sequencing adaptors, and PCR amplification with 8-bp
barcodes for multiplexing. Libraries underwent exome
capture using the Roche/Nimblegen SeqCap EZ v3.0 (w62
MB target) (Roche, Basel, Switzerland). Library quality was
assessed by triplicate quantitative PCR and molecular
weight distributions were verified on the Agilent Bio-
analyzer (consistently 125 ± 15 bp). Pooled, barcoded li-
braries were sequenced via paired-end 50-bp reads with an
8-bp barcode read on Illumina HiSeq2000/2500 sequencers
(Illumina). Unaligned binary format of sequence files (BAM)
files were aligned to a human reference (hg19) using the
Burrows–Wheeler Aligner (v0.6.2). Read data from a flow-
cell-lane were treated independently for alignment and
quality control purposes before merging data to complete
an exome. Sample-level quality control was performed on
merged data after it had met the threshold for coverage
metrics on exome target. Read-pairs not mapping within ±
2 standard deviations of the average library size (w125 ±
15 bp for exomes) were removed. All aligned read data
were subject to the following steps: (1) removal of duplicate
reads using Picard MarkDuplicates v1.70; (2) indel
realignment with the Genome Analysis Toolkit (https://
www.broadinstitute.org/gatk/) IndelRealigner v1.6-11-
g3b2fab9; and (3) base qualities recalibration with
Genome Analysis Toolkit Table Recalibration, variants were
flagged using the filtration walker (Genome Analysis Tool-
kit) to mark sites that were of lower quality or false posi-
tives (eg, low-quality scores [Q50], allelic imbalance [ABHet,
0.75], long homopolymer runs > 3, and/or low quality
by depth < 5). Variants were annotated with the Seat-
tleSeq137 Annotation Server (http://gvs.gs.washington.
edu/SeattleSeqAnnotation).
RAD21 Mutation Screening in Sporadic
CIPO Patients
PCR primers for human RAD21 (NM_006265.2) were
designed with Primer3 v4.0 (http://primer3.ut.ee) and are
available on request. Genomic DNA extracted from periph-
eral blood was amplified according to the following PCR
conditions: 30 ng of DNA, 2.5 mmol/L MgCl2, 0.5 mmol/L
deoxynucleoside triphosphate, 0.5 mmol/L primers, 5%
dimethyl sulfoxide in a final volume of 20 mL using the 2X
KAPA Fast Taq Polymerase Master mix (KAPA Biosystems,
Wilmington, MA). Forty cycles were performed as follows:
95C 10, 95C 1500, 58C 100, and 72C 100, with a final
extension of 3000 at 72C. PCR products were purified onto
Millipore PCR clean-up plates (Millipore, Darmstadt, Ger-
many) and directly sequenced on both strands using the
BigDye v1.1 kit (Life Technologies, Carlsbad, CA). Electro-
pherograms were visualized with Chromas version 2.0
(Chromas, Technelysium, South Brisbane, Australia) and
Sequencer version 4.7.
RAD21 cDNA Transfection Into HEK293 Cells
Human RAD21 cDNA inserted into pCMV6 vector in
frame with DDK epitope was purchased from OriGene
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(OriGene, Rockville, MD). The mutation corresponding to
p.622 Ala>Thr was inserted by site-directed mutagenesis
using the QuickChange XL mutagenesis kit (Agilent Tech-
nologies, Santa Clara, CA) according to the manufacturer’s
instructions. The insertion of the changes was verified by
direct sequencing. HEK293 human renal cells (3  105;
ATCC, Middlesex, UK) were plated for transfection of the
different plasmids using liposomes according to the manu-
facturer’s instructions (Lipofectamine; Life Technologies).
Protein and RNA extraction was performed after 48 hours
from transfection.
Gene Expression Analysis
Total RNA from 1.5 mL fresh blood was extracted with
the Qiagen Blood Total RNA kit (Qiagen). Total RNA from
5  106 LCLs or HEK293 cells, cultured according to stan-
dard protocols, was extracted with the RNeasy kit (Qiagen).
A total of 1 mg of DNase I–treated RNA was used for reverse
transcription with random hexamers using the Multiscribe
RT system (Life Technologies) at 48C for 400 in a final
volume of 50 mL. Quantitative RT-PCR was performed with
SYBRGreen, 0.5 mmol/L primers, in an ABI 7500 Real-Time
PCR System (Life Technologies). All target genes were
normalized with the corresponding endogenous control
(b-actin) using the DDCt comparative method. PCR primers
are available on request.
Immunoprecipitation and Western Blotting
A total of 2  106 LCLs were lysed in 50 mmol/L HEPES,
1 mmol/L EDTA, 10% glycerol, 1% Triton X-100, and 150
mmol/L NaCl in the presence of protease inhibitors (Roche
Diagnostics, Basel, Switzerland), and phosphatase inhibitors
(Inhibition Cocktails 2 and 3; Sigma). Preclearing was per-
formed with rabbit IgG (Millipore) for 1 hour at 4C.
Immunoprecipitation assays were performed at 4C using
0.8 mg rabbit anti-SMC1 or anti-RAD21 antibody/reaction
(Sigma Prestige) on Protein G-Sepharose (Sigma). Proteins
were separated by sodium dodecyl sulfate gel electropho-
resis, transferred onto a nitrocellulose membrane (GE
Healthcare, Little Chalfont, UK), and subjected to Western
blot with the Western Breeze kit (Life Technologies). Pro-
teins extracted from sera of patients were diluted 1:5 in
phosphate-buffered saline, quantified with the Lowry
method and Coomassie Blue gel staining, separated by so-
dium dodecyl sulfate gel electrophoresis, and transferred
onto a nitrocellulose membrane (GE Healthcare). Primary
antibodies used were as follows: goat anti-APOB48 1:250
(Santa Cruz, Dallas, TX), goat anti-APOB 1:1000 (Dako,
Santa Clara, CA), rabbit anti-APOB100 1:200 (Abcam,
Cambridge, UK), and mouse anti–glyceraldehyde-3-
phosphate dehydrogenase (Abcam) diluted at 1:5000.
Bands were visualized using the enhanced chemo-
luminescence method (GE Healthcare).
Zebrafish Functional Assays
To determine the effect of rad21a suppression in
zebrafish embryos, a splice-blocking morpholino was
designed by Gene Tools, LLC (Philomath, OR), rad21a MO
(AGGGTCTGCGTTCCTTGACTTCCAT), targeting the splice
junction at the 3’ end of exon 2. A published ret
MO (ACACGATTCCCCGCGTACTTCCCAT) was used.20 To
measure rad21a MO efficiency, total mRNA was extracted
from control and MO-injected embryos, reverse-transcribed,
and the site targeted by the MO was PCR-amplified using
the following primers: GGGACAAAAAGCTGACCAAA and
CAGGGTGAACTGCTGTGCTA.
For knockdown and rescue experiments, we injected
either 3 ng of rad21 MO (runx1 expression), or 1.2 ng rad21
MO (gut phenotype). For zebrafish injections, capped hu-
man RAD21 mRNA was produced by cloning wild-type
RAD21 cDNA and the 3 mutant constructs (P376R, C585R,
and A622T) into the pCS2þ expression vector and reverse
transcribing each construct in vitro with the SP6 Message
Machine kit (Ambion, Austin, TX).
Injected embryos were fixed at 5 dpf in 4% para-
formaldehyde for 16 hours at 4C, and moved to methanol
at -20C. After rehydration steps in decreasing series of
methanol/PBS containing 0.1% Tween-20, permeabiliza-
tion, postfixation, and blocking, embryos were incubated
with anti-HuC/D antibody (1:500; Life Technologies) for 16
hours at 4C. After washes in PBT, embryos were incubated
with Alexa-488 (1:500; Invitrogen, Carlsbad, CA) as a sec-
ondary antibody. All experiments were repeated 3 times
and the Pearson chi-square test was used to determine
significance.
For in situ analysis, a runx1 probe was designed using
the following primers: AATTAACCCTCACTAAAGGGGC
CACTGCAAGCACCTCTGG and TAATACGACTCACTATAGGA
CGAGGAGAGGACACAAAGC. Digoxigenin-labeled antisense
probe was synthesized using T7 from a plasmid kindly
provided by Kathryn Crosier. Injected embryos (w14 dpf)
were fixed in 4% paraformaldehyde for 16 hours at 4C,
and moved to 100% methanol for storage. After step-wise
rehydration washes, embryos were incubated at 65C
with the runx1 probe. Antidigoxigenin antibodies conju-
gated with alkaline phosphatase antibody were used and
developed with nitro blue tetrazolium (NBT)/5-bromo-4-
chloro-3-indolyl-phosphate (BCIP) as substrate.
Electromobility Shift Assay
LCLs (2  106) were rinsed in cold phosphate-buffered
saline–Na3VO4 0.2 mmol/L, pelleted by centrifugation at
1600g, and lysed in 400 mL of Buffer A (10 mmol/L
HEPES pH 7.9, 10 mmol/L KCl, 0.1 mmol/L EDTA, 1 mmol/
L dithiothreitol, 1 mmol/L Na3VO4, and a protease inhibitor
cocktail) for 15 minutes in ice. A total of 25 mL of 10% NP-
40 was added and the samples were centrifuged at
16,000g for 30 seconds. The nuclear pellets were resus-
pended in 50 mL Buffer C (20 mmol/L HEPES pH 7.9, 0.4
mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L ethylene
glycol-bis[b-aminoethyl ether]-N,N,N0,N0-tetraacetic acid,
1 mmol/L dithiothreitol, 1 mmol/L Na3VO4, and a protease
inhibitor cocktail), incubated on ice for 45 minutes, and
centrifuged at 16,000g for 10 minutes at 4C. Ten mi-
crograms of nuclear extracts, 20 fmol of biotin-labeled
probes, 2 mg of sheared salmon sperm DNA, 2.5%
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glycerol, 5 mmol/L KCl, and 5 mM MgCl2 were incubated at
room temperature for 30 minutes in 20 mL. Cold probes
were added at a concentration of 200. The nuclear com-
plexes were resolved by nondenaturing electrophoresis on
4% polyacrylamide gel, transferred onto a nitrocellulose
membrane at 380 mA for 30 minutes at 4C, and
cross-linked via UV binding for 15 minutes at room
temperature.
For supershift assay, nuclear extracts were incubated at
the same conditions as reported earlier, but the complexes
were immunoprecipitated for 40 minutes at 4C with 1.5 mg
of rabbit anti-RAD21 antibody (Abcam) before the electro-
mobility shift assay assays. Complexes were resolved under
nondenaturing conditions using a 3.5% polyacrylamide gel.
Electromobility shift assay shift was shown with the
LightShift Chemiluminescent Electromobility Shift Assay Kit
(Thermo Scientific, Waltham, MA). The biotin-labeled
probes used were as follows: hAPO_AC2 50-ACGGAGTTGT
CAAGGCGGGGGCTGCAGGCAGAGGGCGCTAAAGAGCCCAGGA
TGGCCGGG-30 (chr11: 116,662,104–116,662,163; hg19);
hAPOB_c1 50-CAGAGCACTGAAGACGCTTGGGGAAGGGAACC
CACCTGGGACCCAGCCCCTGGTGGCTGCGGCTGCAT-30 (chr2:




Immunohistochemistry was performed on paraffin-
embedded adult human colon tissues (patients routinely
underwent surgery for uncomplicated colon cancers
commonly were used as controls for immunohistochemical
experiments) according to protocols validated in our labo-
ratory. Briefly, tissue sections were treated to remove
paraffin embedding by 3 sequential washes in xylene and
graded ethanol. Antigen unmasking was performed by
heating sections at 95C in 10 mmol/L sodium citrate
buffer, pH 6.0, for 10 minutes, and subsequent cooling at
room temperature for 30 minutes. To reduce endogenous
peroxidases, tissue sections were treated with an ad hoc
blocking kit (GeneTex, Inc, Irvine, CA) and incubation for 16
hours at 4C with primary antibodies. The following pri-
mary antibodies were used: anti-human APOB48 (Santa
Cruz) and anti-human APOB diluted 1:100 (Abcam); and
anti-human RAD21 diluted 1:250 (Sigma Prestige) and anti-
human APOBEC1 diluted 1:100 (Creative Diagnostics,
Bristol, UK). Incubations with the corresponding blocking
peptides or with the secondary antibodies were performed
only as negative controls (Supplementary Figure 2A and B).
Fluorescent secondary antibodies were diluted 1:300 in
Triton-X and incubated for 60 minutes at room temperature
before subsequent dehydration and visualization under a
Leica DMLB fluorescent microscope (Leica, Mannheim,
Germany). 3,30-diaminobenzidine tetra hydrochloride
staining was performed according to standard protocols.
Quantitative Evaluation of Ganglion Cells
We counted the number of neurons after immuno-
staining with a rabbit polyclonal anti-human neuronal-
specific enolase antibody 1:400 (Millipore). For each
section, 25–28 high-power (40) microscopic fields, along
the neuromuscular ridge of the myenteric ganglia, were
captured to assess neuronal-specific enolase immunoreac-
tive neuronal cell bodies/ganglion.22 The same procedure
was performed for counting the neurons in the submucosal
ganglia. Sections were examined using a Leica microscope
equipped with a digital camera.
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Supplementary Figure 1. RT-PCR analysis of knockdown
efficiency for splice-site targeted rad21 morpholino. (A)
Schematic of zebrafish rad21. A splice-blocking MO (red bar)
was designed against the second exon–intron junction. PCR
primers (blue bar) designed against exons 1 and 3 were used
to test MO efficiency. (B) In control embryos, there is a single
amplicon, whereas in rad21 MO, there are 2 amplicons,
showing the efficiency of the MO used.
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Supplementary Figure 2. Serial dilutions for APOB48 Western blot and negative controls for immunohistochemistry analysis.
(A) Serial dilutions of sera from CIPO patients and controls; images are representative of replica experiments. (B and C) Images
of negative controls, including primary antibody omission and blocking with the corresponding peptides for (B) APOB and (C)
RAD21 are shown. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Supplementary Figure 3. Functional studies of RAD21 mutation p.622Ala>Thr in vitro. (A) Screenshot of the parallel
sequencing output for the mutation in RAD21 (genomic change). (B and C) RAD21 expression is not altered in (B) patient’s
blood and (C) lymphoblastoid cell lines. RAD21 expression was evaluated by real-time quantitative RT-PCR. (D) RAD21
expression immunoprecipitation analysis for SMC1 and RAD21 from protein extracts of LCLs, showing that the binding is
retained even in the presence of the mutated protein (second lane in each panel). (E) Quantitative RT-PCR for RUNX1
expression in HEK293 cells transfected either with empty, RAD21 wild-type, or RAD21 mutant p.622 Thr vectors. Data
represent the mean values of 3 independent transfection experiments. Bars represent the standard deviation; black asterisk
indicates the significant P value. (Representative Western blot analysis of recombinant RAD21 in frame with the DDK epitope in
the transfected cells is reported in Figure 4C). (F) Electromobility shift assay analysis showing that LCL nuclear extracts
containing either RAD21 wild-type or mutant protein retain the binding ability for the AC2 site on chromosome 11. Black arrows
indicate the gel shifts.
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Supplementary Figure 4. Electromobility shift assays
showing the RAD21-specific supershifts for the 2 regions in
human APOB promoter. Black arrows indicate the shift, grey
stars indicate the supershift observed only in lanes derived
from control nuclear extracts. For the c_1 region the com-
plexes in the supershift were resolved only after a longer gel
run, therefore the free biotin-labelled probes were not
retained in the gel. Images are representative of 3 indepen-
dent experiments.
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Supplementary Figure 5.Western blot for APOB on CIPO and IBS sera. (A) Western blot analysis of APOB100 in sera of CIPO
patient carrying RAD21 mutation, controls, and CIPO patients. (B) Immunoblots showing the increased expression of APOB48
in sera of the CIPO patients included in RAD21 mutation screening, compared with controls. (C) Immunoblots for APOB48 in
IBS vs CIPO patients and controls. Samples loaded in different gels and analyzed for APOB48 expression are shown in bold.
IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS.
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Supplementary Figure 6. RAD21 and APOBEC1 immunostaining. (Ai–iv) RAD21 immunoreactivity in gut biopsy specimens
of (Ai, iii) controls and (Aii, iv) CIPO patients. The representative pictures indicate RAD21 immunolabeling in the nuclei of (Ai, ii)
epithelial and lamina propria immunocyte-like cells as well as (Aiii, iv) myenteric neurons. (Bi–ii) APOBEC1 labeling with
an overlapping immunoreactive pattern to that observed for RAD21, showing no changes in (Bi) controls and (Bii) CIPO
patients.
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Supplementary Table 1. Individual and Shared Runs of Homozygosity in the 3 Affected Siblings
Identification Chromosome SNP start SNP end Start, bp End, bp Length, kb SNPs, n
IV-9 8 rs2737227 rs6998986 116713296 124956205 8242.91 864
IV-10 8 rs2737227 rs6998986 116713296 124956205 8242.91 864
IV-11 8 rs2737227 rs6998986 116713296 124956205 8242.91 864
Overlap 8 rs2737227 rs6998986 116713296 124956205 8242.91 864
IV-11 8 rs6471254 rs1420849 91878147 113307176 21429 2043
IV-10 8 rs1850819 rs1420849 78905837 113307176 34401.3 2964
IV-9 8 rs2622590 rs1420849 56520828 113307176 56786.3 5025
Overlap 8 rs6471254 rs1420849 91878147 113307176 21429 2043
Supplementary Table 2.Cholesterol and HDL Levels in CIPO
Patient reference code Sex Total cholesterol HDL
ITA_CIPO08 M 158 59
ITA_CIPO27 F 154 64
ITA_CIPO37 F 150 53
ITA_CIPO23 M 200 42
ITA_CIPO38 F 168 80
ITA_CIPO29 M 202 49
ITA_CIPO39 F 142 41
ITA_CIPO26 F 181 51
ITA_CIPO24 F 198 48
ITA_CIPO16 F 150 52
ITA_CIPO14 F 200 53
ITA_CIPO33 M 126 25
ITA_CIPO30 F 201 76
NOTE. Normal values for cholesterol are  200; normal
values for HDL are  35.
HDL, high-density lipoprotein.
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